Vascular

Hitinder S. Gurm, MBBS
Department of Cardiovascular Medicine, The Cleveland Clinic

Byron Hoogwerf, MD
Department of Endocrinology and Metabolism; Section of Preventive Cardiology, Department of Cardiovascular Medicine, Director; Internal Medicine Residency Program, The Cleveland Clinic

Address: Hitinder S. Gurm, MBBS, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Hoogwerf has indicated that he is a consultant for Astra Zeneca and Merck, and is on the speakers’ bureau for Merck and Schering Plough.

Hitinder S. Gurm, MBBS
Department of Cardiovascular Medicine, The Cleveland Clinic

Byron Hoogwerf, MD
Department of Endocrinology and Metabolism; Section of Preventive Cardiology, Department of Cardiovascular Medicine, Director; Internal Medicine Residency Program, The Cleveland Clinic

Address: Hitinder S. Gurm, MBBS, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Hoogwerf has indicated that he is a consultant for Astra Zeneca and Merck, and is on the speakers’ bureau for Merck and Schering Plough.

Hitinder S. Gurm, MBBS
Department of Cardiovascular Medicine, The Cleveland Clinic

Byron Hoogwerf, MD
Department of Endocrinology and Metabolism; Section of Preventive Cardiology, Department of Cardiovascular Medicine, Director; Internal Medicine Residency Program, The Cleveland Clinic

Address: Hitinder S. Gurm, MBBS, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Hoogwerf has indicated that he is a consultant for Astra Zeneca and Merck, and is on the speakers’ bureau for Merck and Schering Plough.

Joseph H. Korn, MD
Director, Arthritis Center, Boston University School of Medicine; Chief, Rheumatology Section, Boston Medical Center

Address: Joseph H. Korn, MD, Chief, Rheumatology Section, Boston University Medical Center, 80 East Concord Street, Boston, MA 02118

The author has indicated that he has received grant or research support from the Actelion, Biogen, and Genzyme corporations and from the National Institutes of Health; serves as a consultant for the Actelion and Genzyme corporations; and is on the speaker’s bureau of the Actelion corporation.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Joseph H. Korn, MD
Director, Arthritis Center, Boston University School of Medicine; Chief, Rheumatology Section, Boston Medical Center

Address: Joseph H. Korn, MD, Chief, Rheumatology Section, Boston University Medical Center, 80 East Concord Street, Boston, MA 02118

The author has indicated that he has received grant or research support from the Actelion, Biogen, and Genzyme corporations and from the National Institutes of Health; serves as a consultant for the Actelion and Genzyme corporations; and is on the speaker’s bureau of the Actelion corporation.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Joseph H. Korn, MD
Director, Arthritis Center, Boston University School of Medicine; Chief, Rheumatology Section, Boston Medical Center

Address: Joseph H. Korn, MD, Chief, Rheumatology Section, Boston University Medical Center, 80 East Concord Street, Boston, MA 02118

The author has indicated that he has received grant or research support from the Actelion, Biogen, and Genzyme corporations and from the National Institutes of Health; serves as a consultant for the Actelion and Genzyme corporations; and is on the speaker’s bureau of the Actelion corporation.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Raed H. Abdelhadi, MD
Department of Internal Medicine, The Cleveland Clinic

Curtis M. Rimmerman, MD
Head, Section of Clinical Electrocardiography, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Curtis M. Rimmerman, MD, Department of Cardiovascular Medicine, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail: [email protected]

Raed H. Abdelhadi, MD
Department of Internal Medicine, The Cleveland Clinic

Curtis M. Rimmerman, MD
Head, Section of Clinical Electrocardiography, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Curtis M. Rimmerman, MD, Department of Cardiovascular Medicine, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail: [email protected]

Raed H. Abdelhadi, MD
Department of Internal Medicine, The Cleveland Clinic

Curtis M. Rimmerman, MD
Head, Section of Clinical Electrocardiography, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Curtis M. Rimmerman, MD, Department of Cardiovascular Medicine, F15, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, e-mail: [email protected]

Paul Schoenhagen, MD
Section of Cardiovascular Imaging, Department of Radiology, and Department of Cardiovascular Medicine, The Cleveland Clinic

Richard D. White, MD
Head, Section of Cardiovascular Imaging, Department of Radiology, and Department of Cardiovascular Medicine, The Cleveland Clinic

Steven E. Nissen, MD
Medical Director, Cardiovascular Coordinating Center, Department of Cardiovascular Medicine, The Cleveland Clinic

E. Murat Tuzcu, MD
Director, Intravascular Laboratory, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: E. Murat Tuzcu, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Paul Schoenhagen, MD
Section of Cardiovascular Imaging, Department of Radiology, and Department of Cardiovascular Medicine, The Cleveland Clinic

Richard D. White, MD
Head, Section of Cardiovascular Imaging, Department of Radiology, and Department of Cardiovascular Medicine, The Cleveland Clinic

Steven E. Nissen, MD
Medical Director, Cardiovascular Coordinating Center, Department of Cardiovascular Medicine, The Cleveland Clinic

E. Murat Tuzcu, MD
Director, Intravascular Laboratory, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: E. Murat Tuzcu, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

Paul Schoenhagen, MD
Section of Cardiovascular Imaging, Department of Radiology, and Department of Cardiovascular Medicine, The Cleveland Clinic

Richard D. White, MD
Head, Section of Cardiovascular Imaging, Department of Radiology, and Department of Cardiovascular Medicine, The Cleveland Clinic

Steven E. Nissen, MD
Medical Director, Cardiovascular Coordinating Center, Department of Cardiovascular Medicine, The Cleveland Clinic

E. Murat Tuzcu, MD
Director, Intravascular Laboratory, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: E. Murat Tuzcu, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: [email protected]

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

Michael Miller, MD
Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, Baltimore

Address: Michael Miller, MD, Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, 22 South Greene St., Room 53B06, Baltimore, MD 21201; e-mail: [email protected]

The author has indicated that he has received grant or research support from the Merck, Pfizer, Kos Pharmaceuticals, and AstraZeneca corporations.

Michael Miller, MD
Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, Baltimore

Address: Michael Miller, MD, Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, 22 South Greene St., Room 53B06, Baltimore, MD 21201; e-mail: [email protected]

The author has indicated that he has received grant or research support from the Merck, Pfizer, Kos Pharmaceuticals, and AstraZeneca corporations.

Michael Miller, MD
Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, Baltimore

Address: Michael Miller, MD, Director, Center for Preventive Cardiology, Department of Medicine and Epidemiology, University of Maryland Medical Center, 22 South Greene St., Room 53B06, Baltimore, MD 21201; e-mail: [email protected]

The author has indicated that he has received grant or research support from the Merck, Pfizer, Kos Pharmaceuticals, and AstraZeneca corporations.

Gian M. Novaro, MD
Department of Cardiovascular Medicine, The Cleveland Clinic, Weston, Florida

Brian P. Griffin, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Brian P. Griffin, MD, Section of Cardiovascular Imaging, F15, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44122; e-mail: [email protected]

Dr. Novaro has indicated that he has received grant or research support from Pfizer Inc.

Dr. Griffin has indicated that he is on the speakers' bureau of the Merck corporation and has received grant or research support from Pfizer Inc.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Gian M. Novaro, MD
Department of Cardiovascular Medicine, The Cleveland Clinic, Weston, Florida

Brian P. Griffin, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Brian P. Griffin, MD, Section of Cardiovascular Imaging, F15, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44122; e-mail: [email protected]

Dr. Novaro has indicated that he has received grant or research support from Pfizer Inc.

Dr. Griffin has indicated that he is on the speakers' bureau of the Merck corporation and has received grant or research support from Pfizer Inc.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Gian M. Novaro, MD
Department of Cardiovascular Medicine, The Cleveland Clinic, Weston, Florida

Brian P. Griffin, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Brian P. Griffin, MD, Section of Cardiovascular Imaging, F15, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44122; e-mail: [email protected]

Dr. Novaro has indicated that he has received grant or research support from Pfizer Inc.

Dr. Griffin has indicated that he is on the speakers' bureau of the Merck corporation and has received grant or research support from Pfizer Inc.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Gregg C. Fonarow, MD
Director, Ahmanson-UCLA Cardiomyopathy Center, Director Cardiology Fellowship Training Program, Co-Director, UCLA Preventative Cardiology Program, Associate Professor of Medicine, UCLA Division of Cardiology

Address: Gregg C. Fonarow, MD, Division of Cardiology, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095; e-mail: [email protected]

The author has indicated that he has received grant and research support from Pfizer, Merck, Bristol-Myers Squibb, and GlaxoSmithKline corporations.

His lecture at The Cleveland Clinic Division of Medicine Grand Rounds was funded in part by an unrestricted educational grant from Pfizer.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Gregg C. Fonarow, MD
Director, Ahmanson-UCLA Cardiomyopathy Center, Director Cardiology Fellowship Training Program, Co-Director, UCLA Preventative Cardiology Program, Associate Professor of Medicine, UCLA Division of Cardiology

Address: Gregg C. Fonarow, MD, Division of Cardiology, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095; e-mail: [email protected]

The author has indicated that he has received grant and research support from Pfizer, Merck, Bristol-Myers Squibb, and GlaxoSmithKline corporations.

His lecture at The Cleveland Clinic Division of Medicine Grand Rounds was funded in part by an unrestricted educational grant from Pfizer.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Gregg C. Fonarow, MD
Director, Ahmanson-UCLA Cardiomyopathy Center, Director Cardiology Fellowship Training Program, Co-Director, UCLA Preventative Cardiology Program, Associate Professor of Medicine, UCLA Division of Cardiology

Address: Gregg C. Fonarow, MD, Division of Cardiology, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095; e-mail: [email protected]

The author has indicated that he has received grant and research support from Pfizer, Merck, Bristol-Myers Squibb, and GlaxoSmithKline corporations.

His lecture at The Cleveland Clinic Division of Medicine Grand Rounds was funded in part by an unrestricted educational grant from Pfizer.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Stephen B. Levine, MD
Clinical Professor of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH; Co-Director, Center for Marital and Sexual Health, and President, Center for Sexual Health Research, Beachwood, OH

Address: Stephen B. Levine, MD, Center for Marital and Sexual Health, 3 Commerce Park Square, Suite 350, Beachwood, OH 44122-5402

The author has indicated that he has received grant or research support from Pfizer corporation, is a consultant for Lilly-ICOS, and is on the speakers' bureaus of the Consortium for Improvement in Erectile Function and Pfizer.

The presentation on which this article is based was supported by an unrestricted educational grant from Lilly-ICOS LLC.

This article discusses therapies that are not approved by the US Food and Drug Administration.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Stephen B. Levine, MD
Clinical Professor of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH; Co-Director, Center for Marital and Sexual Health, and President, Center for Sexual Health Research, Beachwood, OH

Address: Stephen B. Levine, MD, Center for Marital and Sexual Health, 3 Commerce Park Square, Suite 350, Beachwood, OH 44122-5402

The author has indicated that he has received grant or research support from Pfizer corporation, is a consultant for Lilly-ICOS, and is on the speakers' bureaus of the Consortium for Improvement in Erectile Function and Pfizer.

The presentation on which this article is based was supported by an unrestricted educational grant from Lilly-ICOS LLC.

This article discusses therapies that are not approved by the US Food and Drug Administration.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

Stephen B. Levine, MD
Clinical Professor of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH; Co-Director, Center for Marital and Sexual Health, and President, Center for Sexual Health Research, Beachwood, OH

Address: Stephen B. Levine, MD, Center for Marital and Sexual Health, 3 Commerce Park Square, Suite 350, Beachwood, OH 44122-5402

The author has indicated that he has received grant or research support from Pfizer corporation, is a consultant for Lilly-ICOS, and is on the speakers' bureaus of the Consortium for Improvement in Erectile Function and Pfizer.

The presentation on which this article is based was supported by an unrestricted educational grant from Lilly-ICOS LLC.

This article discusses therapies that are not approved by the US Food and Drug Administration.

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.